Because the majority of erbB2-overexpressing (erbB2-positive) breast cancer cells express little or basal levels of EGFR, lapatinib mainly inhibits erbB2 kinase activity (intracellular domain) in erbB2-positive breast cancers. This evidence concerns the gene EGFR and breast cancer.